Tris Pharma Presents New Clinical Data Demonstrating Robust Safety and Efficacy of Investigational, First-in-Class Therapy Cebranopadol for Treatment of Pain (Businesswire) - Aug 6, 2024 - "Tris Pharma, Inc...today announced new clinical data demonstrating that cebranopadol...produces significantly less respiratory depression than oxycodone. The findings will be highlighted in a poster session on August 7, 2024, at the International Association for the Study of Pain (IASP) 2024 World Congress on Pain in Amsterdam....At equianalgesic doses, cebranopadol produces 25% less respiratory depression compared to oxycodone. Treatment with cebranopadol presents a longer time to impact on respiratory parameters compared to oxycodone, allowing for the gradual accumulation of arterial CO2 and mitigating the full manifestation of respiratory depression. Cebranopadol achieved prolonged analgesic effects with gradual onset and offset. Despite having a longer duration of effect, cebranopadol produces fewer respiratory adverse events over 24 hours..."
Clinical data • Back Pain • CNS Disorders • Neuralgia • Osteoarthritis • Pain
|